

Prematurely ended - Statement

EudraCT Number:	2006-001269-40
Full title of the study:	Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Therapy AN OPEN-LABEL, CONTROLLED, PHASE II MULTICENTER TRIAL OF IMMUNOABLATIVE CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE AND ANTI-THYMOCYTE GLOBULIN AND TRANSPLANTATION OF PURIFIED CD34+ AUTOLOGOUS HEMAPOIETIC STEM CELLS VERSUS CURRENTLY AVAILABLE IMMUNOSUPPRESSIVE THERAPY FOR THE TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS.
Sponsor-Code:	CT-1306
Sponsor:	Charité – Universitätsmedizin Berlin
PI:	Prof. med Falk Hiepe
Date of early termination:	27/11/2023
Statement:	Due to the insufficient number of patients recruited since the study began in 2008 (only 10 out of 30 planned). One possible reason was the market approval of novel biological therapies for SL, which led to reduced medical need and less engagement on the part of participating sites and patients.